Middle East & Africa Glaucoma Therapeutics Market

The Middle East & Africa glaucoma therapeutics market was valued at US$ 518.94 million in 2023 and is expected to reach US$ 638.34 million by 2031; it is estimated to register a CAGR of 2.6% from 2023 to 2031.

Development of Novel Drug Delivery Methods Fuels Middle East & Africa Glaucoma Therapeutics Market

One of the most common treatment approaches for glaucoma management is to reduce intraocular pressure by using eye drops. Nonetheless, the rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market in the future. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the better bioavailability and efficacy of drugs. Sustained release (SR) implants and other innovative drug delivery systems aid in improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers associated with the treatment of primary open-angle glaucoma (POAG). As per an article published in PubMed Central in 2022, the only approved SR therapy for POAG by the FDA is Bimatoprost SR (DurystaTM) from Allergan plc. Bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are among other SR therapies that are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods is likely to remain a key trend in the glaucoma therapeutics market.

Middle East & Africa Glaucoma Therapeutics Market Overview

The Middle East & Africa glaucoma therapeutics market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The increasing prevalence of glaucoma in the geriatric population of the region and the rising government initiatives to spread awareness about the disease are fueling the growth of the glaucoma therapeutics market in the Middle East & Africa. According to an article published by IAPB in March 2020, congenital glaucoma, caused by an abnormality in the drainage outflow of the eye, is a leading cause of childhood blindness in Saudi Arabia. Approximately 8,000 children are estimated to have a functional low vision in the country. Children often suffer from severe conditions, necessitating multiple procedures and lifelong medical care, placing a significant social and economic burden on affected individuals and their families. Various research institutes in the region are engaged in developing and implementing treatments for glaucoma management. For instance, in an article published in JBI Evidence Implementation in June 2021, a pilot project implementation was inspected to evaluate adherence to evidence-based criteria and to introduce a modified clinical practice guideline (CPG) for treating patients with primary open-angle glaucoma (POAG) at a specialized eye care center in Riyadh, Saudi Arabia. The assessment showed that audit and feedback are effective tools for changing glaucoma practices in hospital in Saudi Arabia. This signifies that the project implementation can be generalized to promote evidence-based ophthalmology practices and may improve quality and consistency and optimize patients' care. Thus, the increase in research and development activities to treat glaucoma in the country is likely to support market growth during the forecast period.

Middle East & Africa Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Glaucoma Therapeutics Strategic Insights

Strategic insights for the Middle East & Africa Glaucoma Therapeutics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Glaucoma Therapeutics Report Scope

Middle East & Africa Glaucoma Therapeutics Regional Insights

The geographic scope of the Middle East & Africa Glaucoma Therapeutics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Glaucoma Therapeutics Market Segmentation 

The Middle East & Africa glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Middle East & Africa glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Middle East & Africa glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Middle East & Africa glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Middle East & Africa glaucoma therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Middle East & Africa glaucoma therapeutics market.